- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01630044
Neurostimulation Device for Treatment of Migraine Headache
March 25, 2025 updated by: Scion NeuroStim
Clinical Pilot Study to Evaluate a Non-Invasive, Neurostimulation Device for Treatment of Migraine Headache
This is a single-site, prospective, non-randomized and open label study to investigate the feasibility of home-use CVS for the prevention of episodic migraine headache and specifically to better understand what type of waveform to apply.
Study Overview
Detailed Description
This study is a single-center, unblinded, non-randomized clinical trial for adjunctive prophylactic treatment of episodic migraine headache using neuromodulation device developed by Scion NeuroStim, LLC (SNS).
The investigational use of the device for episodic migraine headache has been reviewed by the FDA and is classified as NSR (non-significant risk).
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Medicine / Neurology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- A history of at least four, and not more than fourteen total monthly headache days of which between four and nine were migraine headache days. (Note: Patients were permitted continued access to migraine abortive medications and were being treated at the Duke University headache clinic.)
- A history of some responsiveness (incomplete) to at least one and a maximum of two prophylactic pharmaceutical therapies (utilized concurrently);
- The investigator must have confidence in the patient's ability to reliably complete and return the Daily Headache Diary.
- Subject must be at least 18 years of age.
Exclusion Criteria:
- Individuals who were pregnant, who had a history of cardiovascular disease, who worked night shifts or who had vestibular migraine, menstrual migraine, post-traumatic migraine, a history of unstable mood disorder or unstable anxiety, moderate or greater hearing loss or a history of traumatic brain injury.
- A history within the last six months of tobacco use, narcotic or barbiturates use or experiencing one or more analgesic rebound headaches.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TNM device, active treatment
This is an active-only assessment of the experimental neuromodulation device
|
Non-invasive neurostimulator, home-use treatment for up to 43 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of migraine headache days
Time Frame: Length of the study, about 71 days
|
Daily Headache Diary will be used by subject.
A headache day is defined as a twenty-four hour period which the subject has a headache.
|
Length of the study, about 71 days
|
|
Severity of each and of all headaches
Time Frame: Length of study, 71 days
|
Daily Headache Diary will be used by subject.
Subject will assign the level of pain based on an eleven-point pain measurement scale from zero (no pain) to ten (most intense pain).
|
Length of study, 71 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Monthly Headache Pain Score
Time Frame: Length of study, about 71 days
|
The monthly measure would be the cumulative maximal headache pain scores for all headache days (days on which the subject's head pain level is one or higher on the pain measurement scale) during the month.
|
Length of study, about 71 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Daniel Laskowitz, MD, Duke University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
June 5, 2012
First Submitted That Met QC Criteria
June 26, 2012
First Posted (Estimated)
June 28, 2012
Study Record Updates
Last Update Posted (Actual)
March 30, 2025
Last Update Submitted That Met QC Criteria
March 25, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00037089
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Headache
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingMigraine | Migraine Headache | Migraine Without Aura | Migraine with Aura | Chronic Migraine, Headache | Episodic Migraine | Chronic Migraine Headache | Headache (Migraine) | Episodic Migraine HeadacheSpain
-
University Medical Centre LjubljanaActive, not recruitingMigraine | Migraine Headache | Migraine Headache, With or Without Aura | Migraine in AdultsSlovenia
-
Ain Shams UniversityRecruitingMigraine | Migraine Headache | Migraine, Acute | Migraine Headache, With or Without Aura | Migraine DiseaseEgypt
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Fundación de Investigación Biomédica - Hospital...Hospital Universitario La Fe; Hospital Vall d'Hebron; Hospital Universitario... and other collaboratorsRecruitingMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With AuraSpain
-
Johns Hopkins UniversityMedtronicRecruitingMigraine | Chronic Migraine Headache | Refractory MigraineUnited States
-
Ariston Pharmaceuticals, Inc.UnknownMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With AuraFinland, Netherlands, United Kingdom
-
Danish Headache CenterCompletedHeadache, Migraine | AuraDenmark
-
TheranicaActive, not recruitingMigraine | Chronic Migraine HeadacheUnited States
-
Benfida, a department of Handi-MoveArtialisRecruitingMigraine | Migraine Headache | Migraine in AdultsBelgium
Clinical Trials on TNM device
-
Scion NeuroStimCompletedParkinson Disease | Parkinson's Disease and ParkinsonismUnited States, United Kingdom
-
Duke UniversityScion NeuroStimCompleted
-
Scion NeuroStimDuke UniversityCompletedPost-stroke AphasiaUnited States
-
Scion NeuroStimTerminatedType 2 DiabetesUnited States
-
Scion NeuroStimTerminatedParkinson's DiseaseUnited States
-
Wake Forest University Health SciencesWithdrawnSubstance Use DisordersUnited States
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)Not yet recruiting
-
MedtronicNeuroCompletedOveractive BladderUnited States
-
VA Office of Research and DevelopmentUS Department of Veterans AffairsCompleted
-
MedtronicNeuroCompletedOveractive BladderUnited States